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Voltage-gated calcium 3.1 (CaV3.1) channels are absent in healthy
mouse β cells and mediate minor T-type Ca2+ currents in healthy
rat and human β cells but become evident under diabetic condi-
tions. Whether more active CaV3.1 channels affect insulin secretion
and glucose homeostasis remains enigmatic. We addressed this
question by enhancing de novo expression of β cell CaV3.1 chan-
nels and exploring the consequent impacts on dynamic insulin
secretion and glucose homeostasis as well as underlying molecular
mechanisms with a series of in vitro and in vivo approaches.
We now demonstrate that a recombinant adenovirus encoding
enhanced green fluorescent protein–CaV3.1 subunit (Ad-EGFP-
CaV3.1) efficiently transduced rat and human islets as well as dis-
persed islet cells. The resulting CaV3.1 channels conducted typical
T-type Ca2+ currents, leading to an enhanced basal cytosolic-free
Ca2+ concentration ([Ca2+]i). Ad-EGFP-CaV3.1-transduced islets re-
leased significantly less insulin under both the basal and first
phases following glucose stimulation and could no longer normalize
hyperglycemia in recipient rats rendered diabetic by streptozotocin
treatment. Furthermore, Ad-EGFP-CaV3.1 transduction reduced phos-
phorylated FoxO1 in the cytoplasm of INS-1E cells, elevated FoxO1
nuclear retention, and decreased syntaxin 1A, SNAP-25, and syn-
aptotagmin III. These effects were prevented by inhibiting CaV3.1
channels or the Ca2+-dependent phosphatase calcineurin. En-
hanced expression of β cell CaV3.1 channels therefore impairs in-
sulin release and glucose homeostasis by means of initial excessive
Ca2+ influx, subsequent activation of calcineurin, consequent de-
phosphorylation and nuclear retention of FoxO1, and eventual
FoxO1-mediated down-regulation of β cell exocytotic proteins.
The present work thus suggests an elevated expression of CaV3.1
channels plays a significant role in diabetes pathogenesis.
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Multiple types of voltage-gated calcium (CaV) channels, in-cluding CaV3.1, operate in the pancreatic β cell mediating
Ca2+ influx in response to membrane depolarization evoked by
increased blood glucose (1–7). Ca2+ influx through all types of
CaV channels and Ca
2+ mobilization mediated by intracellular
Ca2+-release channels in the β cell regulate glucose-stimulated
insulin secretion (1, 5–8). In this context, β cell CaV1 channels
serve as a predominant player compared to other types of β cell
CaV channels due to an optimal elevation in cytosolic free Ca
2+
concentration ([Ca2+]i) within exocytotic sites (1, 5–7). This opti-
mally elevated [Ca2+]i allosterically initiates direct interactions
between exocytotic proteins such as VAMP-2, synaptotagmins III
and VII in the insulin granule membrane, and syntaxin 1A and
SNAP-25 in the plasma membrane (5–7, 9). These interactions
trigger fusion of insulin granules with the plasma membrane to
form fusion pores for insulin cargo release in the first phase of
glucose stimulation (5–7, 9). It is most likely that Ca2+ influx
mediated by other types of β cell CaV channels mildly raises
[Ca2+]i in regions which do not overlap well with exocytotic sites
(5–7). This appears to facilitate trafficking of insulin granules to
the readily releasable pool to be involved in late-phase but not
early-phase glucose-stimulated insulin secretion (5–7). Although it
has been suggested that physiological Ca2+ influx through CaV3
channels participates in glucose-stimulated insulin secretion, the
underlying mechanisms are not known (6, 7, 10, 11).
The CaV3.1 channel is absent in healthy mouse β cells, whereas
it resides in healthy rat and human β cells to conduct T-type Ca2+
currents, accounting for only a minor proportion of total CaV
currents (6, 7, 10, 12, 13). T-type Ca2+ currents appear in diabetic
mouse β cells and are significantly increased in diabetic rat β cells
(14, 15). Despite little understanding of the physiological role of
the CaV3.1 channel in the β cell, there is a possibility that this
Ca2+ channel affects expression of exocytotic proteins under di-
abetic conditions (6, 7). Ca2+-dependent protein phosphatase
calcineurin (CaN) undergoes activation when [Ca2+]i increases
(16). Activated CaN may suppress the expression of exocytotic
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proteins through dephosphorylation of FoxO1 (17–19). Systemic
administration of CaV3 channel blockers significantly ameliorates
hyperglycemia in diabetic mice (20). However, the causal role and
transcriptomic impact of a pathological elevation of β cell CaV3.1
channels in the development of diabetes is not known. We hy-
pothesized that excessive Ca2+ influx through up-regulated CaV3.1
channels drives β cell dedifferentiation by constitutively hyper-
activating CaN and downstream FoxO1 signaling. This is likely to
result in impaired expression of β cell exocytotic proteins, dis-
turbed insulin secretion, aberrant glucose homeostasis, and con-
sequent diabetes. Our results verify that the hypothesized signaling
pathway indeed operates in β cells up-expressing CaV3.1 channels,
suggesting their important role in the pathogenesis of diabetes.
This also means that CaV3.1 channels may serve as potential
druggable targets in the treatment of diabetes.
Results and Discussion
Ad-EGFP-CaV3.1 Efficiently Transduces COS-7 and Rat Islet Cells, and
Expressed EGFP-CaV3.1 Conducts Typical T-Type Ca
2+ Currents.
Recombinant adenovirus vectors have been verified to efficiently
transduce islets (21). To elevate CaV3.1 channel expression in rat
islets, we constructed recombinant adenoviruses carrying either
enhanced green fluorescent protein (Ad-EGFP) or the EGFP-
CaV3.1 subunit (Ad-EGFP-CaV3.1) and characterized them in
COS-7 cells. Ad-EGFP (SI Appendix, Fig. S1 A, Top) and Ad-
EGFP-CaV3.1 (SI Appendix, Fig. S1 A, Bottom) were efficiently
expressed in COS-7 cells. Ad-EGFP-CaV3.1-positive cells dis-
played typical T-type Ca2+ currents characterized by tiny unitary
conductance and fast inactivation (SI Appendix, Fig. S1 B, Right),
whereas Ad-EGFP-positive cells showed no Ca2+ currents (SI
Appendix, Fig. S1 B, Left). Furthermore, the former cells expressed
genuine whole-cell T-type Ca2+ currents, which were tran-
siently activated at more negative membrane potentials (SI Ap-
pendix, Fig. S1C, third and fourth panels), but the latter cells did
not (SI Appendix, Fig. S1C, second panel). The effective ex-
pression and adequate functionality of Ad-EGFP-CaV3.1 in COS-7
cells offer a promising basis for elevation of CaV3.1 channels in
rat islets.
We characterized expression and functionality of Ad-EGFP-
CaV3.1 in dispersed rat islet cells using the same experimental
approaches as employed in the above experiments. We observed
that both Ad-EGFP-infected (SI Appendix, Fig. S2, Top) and Ad-
EGFP-CaV3.1-infected islet cells (SI Appendix, Fig. S2, Bottom)
emitted intense EGFP fluorescence. This substantiates that these
recombinant adenoviral vectors can effectively express the EGFP
and CaV3.1 genes in these cells. We also visualized 2 inward
current components, peaking at about −45 and −5 mV, in con-
trol cells and cells transduced with Ad-EGFP- or Ad-EGFP-
CaV3.1 (Fig. 1A). The first component, i.e., low CaV currents,
was significantly greater in Ad-EGFP-CaV3.1-treated cells than
in control cells or cells infected with Ad-EGFP (Fig. 1 A and B).
However, there was no obvious difference in the second com-
ponent, namely, high CaV currents, between these 3 types of cells
(Fig. 1 A and B). The data reveal that Ad-EGFP-CaV3.1 can
satisfactorily transduce dispersed rat islet cells and compel these
cells to additionally express functional CaV3.1 channels, thereby
enhancing T-type Ca2+ currents.
It should be pointed out that we rarely visualized EGFP fluo-
rescence in the plasma membrane of EGFP-CaV3.1-positive COS-
7 (SI Appendix, Fig. S1A) and islet cells (SI Appendix, Fig. S2).
Nevertheless, we could exclusively detect whole-cell T-type Ca2+
currents in these cells. This is due to the fact that a limited number
of EGFP-CaV3.1 channels scatter throughout the plasma mem-
brane and have a low probability of appearing in the tiny pro-
portion of the plasma membrane in the focal plane of the confocal
microscope.
Ad-EGFP-CaV3.1-Transduced Islets Display Impairments in Both Basal
and First-Phase Glucose-Stimulated Insulin Secretion and Elevation in
Basal [Ca2+]i. Successful transduction of COS-7 and dispersed islet
cells does not necessarily mean that the same thing should
happen in intact islets, which are more difficult to transduce (22).
Therefore, we evaluated the efficiency of infection of rat and hu-
man islets with Ad-EGFP-CaV3.1. Both Ad-EGFP (SI Appendix,
Fig. S3A and B, Top 2 panels) and Ad-EGFP-CaV3.1 (SI Appendix,
Fig. 1. Effects of Ad-EGFP-CaV3.1 transduction on whole-cell CaV currents in
dispersed islet cells and on glucose-stimulated insulin secretion and [Ca2+]i in
islets. (A) Sample whole-cell CaV current traces from a control rat islet cell
and a rat islet cell transduced with Ad-EGFP or Ad-EGFP-CaV3.1. (B) Average
Ca2+ current density–voltage relationships in control (n = 13), Ad-EGFP (n =
11), and Ad-EGFP-CaV3.1 (n = 12) groups. **P < 0.01 vs. control and Ad-EGFP.
(C and D) Dynamic insulin secretion from control, Ad-EGFP-transduced, and
Ad-EGFP-CaV3.1-transduced rat (C) and human (D) islets perifused with 3 mM
glucose (3G) followed by 16.7 mM glucose (16.7G). **P < 0.01 and *P < 0.05 vs.
control and Ad-EGFP. Control rat islets (n = 13), Ad-EGFP-transduced rat islets
(n = 10), Ad-EGFP-CaV3.1-transduced rat islets (n = 10), Ad-EGFP-transduced
human islets (n = 6), and Ad-EGFP-CaV3.1-transduced human islets (n = 6). (E)
Sample [Ca2+]i traces registered in Ad-EGFP- and Ad-EGFP-CaV3.1-transduced
rat (Upper) and human (Lower) islets following perifusion with 3 mM (3G)
and 16.7 mM glucose (16.7 G) as well as 25 mM KCl (25K). (F) Quantitative
analysis of average fura-2 F340/F380 ratios during exposure to 3 mM glucose
and stimulation with 16.7 mM glucose and peak fura-2 F340/F380 ratios in
response to 25 mM KCl in Ad-EGFP-transduced (n = 12) and Ad-EGFP-CaV3.1-
transduced (n = 13) rat islets (Upper) and human islets (n = 9 for Ad-EGFP and
n = 12 for Ad-EGFP-CaV3.1) (Lower). **P < 0.01 and *P < 0.05 vs. Ad-EGFP.




























Fig. S3 A and B, Bottom 2 panels) satisfactorily infected islet cells
within intact islets that emit intense EGFP fluorescence. This
means that the CaV3.1 gene in Ad-EGFP-CaV3.1 can be efficiently
expressed in cells within intact islets. Pancreatic β cells are spe-
cialized for glucose-stimulated insulin secretion (6, 7, 12). The
importance of any molecular constituent of the β cell should be
reflected upon by the extent and severity of impairment in glucose-
stimulated insulin secretion when altered. To explore the impor-
tance of CaV3.1 channels in β cells, we analyzed dynamic glucose-
stimulated insulin secretion from rat and human islets transduced
with Ad-EGFP-CaV3.1. Ad-EGFP-CaV3.1-transduced islets re-
leased significantly less insulin during perifusion with 3 mM glucose
compared to control islets and islets treated with Ad-EGFP (Fig.
1 C and D). Importantly, Ad-EGFP-CaV3.1-transformed islets
displayed a selective impairment in first-phase glucose-stimulated
insulin secretion with intact second-phase insulin response when
exposed to 16.7 mM glucose (Fig. 1 C and D). Moreover, elevated
expression of β cell CaV3.1 channels impaired glucose-stimulated
insulin secretion not only from rat but also human islets. These
data suggest that the pathologically enhanced expression of β cell
CaV3.1 channels serves as a causal factor for defective insulin se-
cretion from human and rodent islets, regardless of obvious in-
terspecies differences in expression of CaV3.1 channels in healthy β
cells (6, 7, 10, 12, 13). This is well supported by the findings of the
appearance of T-type Ca2+ currents in diabetic mouse β cells, el-
evation of these Ca2+ currents in diabetic rat β cells, and, in par-
ticular, amelioration of hyperglycemia by systemic inhibition of
these Ca2+ currents in diabetic mice (6, 7, 12, 14, 15, 20). Taken
together, the findings indicate the significance of up-regulation of
β cell CaV3.1 channels in the pathogenesis of human diabetes.
CaV3.1 channels exist primarily for mediating Ca
2+ influx into
the cytosolic compartment to participate in the formation of [Ca2+]i
dynamics that regulates glucose-stimulated insulin secretion and
maintains β cell specificity (1, 5–7). This prompted us to examine
whether Ad-EGFP-CaV3.1 transduction altered [Ca
2+]i dynamics,
leading to impaired glucose-stimulated insulin secretion. It turned
out that both Ad-EGFP-CaV3.1-transduced rat and human islets
showed significant elevations in [Ca2+]i during perifusion with
3 mM glucose and stimulation with 16.7 mM glucose or 25 mM
KCl compared to those treated with Ad-EGFP (Fig. 1 E and F).
[Ca2+]i curves registered from Ad-EGFP-CaV3.1-transduced islets
were shifted upwards in comparison to those from islets trans-
duced with Ad-EGFP (Fig. 1 E and F). These results substantiate
the importance of the up-expressed CaV3.1 channels in rear-
ranging [Ca2+]i dynamics and thereby elevation in [Ca
2+]i in islets.
However, intuitively, such an elevation in [Ca2+]i should promote
insulin secretion by allosterically triggering Ca2+-dependent
SNARE interactions (23–25). This suggests that elevated [Ca2+]i
in Ad-EGFP-CaV3.1-transduced islets may switch on other
mechanisms to impair insulin secretion. Previous studies indicate
the possibility that the elevation in basal [Ca2+]i following Ad-
EGFP-CaV3.1 transduction may activate CaN to dephosphorylate
FoxO1, inducing its nuclear retention and down-regulation of some
exocytotic proteins (17–19).
Islets Transduced with Ad-EGFP-CaV3.1 Lose Their Ability to Normalize
Hyperglycemia in Streptozotocin-Induced Diabetic Rats. The im-
pairment of first-phase glucose-stimulated insulin secretion rep-
resents the initial defect of β cell function and plays an important
role in glucose intolerance during diabetes development (26–28).
This prompted us to investigate the in vivo pathological role of
Ad-EGFP-CaV3.1-transduced islets that exhibited defective basal
insulin release and first-phase glucose-stimulated insulin secretion.
We compared the abilities of control, Ad-EGFP-infected, and
Fig. 2. Effects of Ad-EGFP-CaV3.1 transduction on antihyperglycemic ability of islets transplanted into the anterior chamber of the eye (ACE) of rats rendered
diabetic with STZ injection. (A) Experimental protocol illustrating time points of STZ injection, islet transplantation, blood glucose test, and in vivo microscopy.
(B) Stereomicroscopic photographs showing aggregated islets engrafted on the rat iris illuminated by visible light (Left) and EGFP fluorescence from these islet
aggregates detected using the GFP filter set (Right). Control, Ad-EGFP-transduced, and Ad-EGFP-CaV3.1-transduced islets are shown in the Top, Middle, and Bottom
microphotographs, respectively. (Scale bars, 1 mm.) (C) Sample confocal images (Left) of control (Top microphotograph), Ad-EGFP-transduced (Middle microphoto-
graph), and Ad-EGFP-CaV3.1-transduced (Bottommicrophotograph) islets engrafted on the rat iris. Green and red represent EGFP fluorescence from Ad-EGFP- and Ad-
EGFP-CaV3.1-transduced islets and Texas Red fluorescence from vasculatures filled with 70 kDa dextran-conjugated Texas Red, respectively. Corresponding reflected-
light images (Right) of control (Top microphotograph), Ad-EGFP-transduced (Middle microphotograph), and Ad-EGFP-CaV3.1-transduced (Bottom microphotograph)
islets engrafted on the rat iris. (Scale bars, 50 μm.) (D) Quantifications of blood glucose levels in STZ-treated rats transplanted with control islets (n = 6) and islets
transduced with Ad-EGFP (n = 6) or Ad-EGFP-CaV3.1 (n = 6) before and after STZ injection and 4 wk after islet transplantation. **P < 0.01 vs. Ad-EGFP-CaV3.1.





















Fig. 3. Effects of Ad-EGFP-CaV3.1 transduction in combination with inhibition of CaV3.1 channels or calcineurin on p-FoxO1, FoxO1, syntaxin 1A, SNAP-25,
and synaptotagmin III and VII levels. (A) Representative blots of cytoplasmic p-FoxO1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) bands in
control INS-1E cells and cells transduced with Ad-EGFP, Ad-EGFP-CaV3.1, or Ad-EGFP-CaV3.1 in the presence of NNC55-0396. (B) Quantifications of p-FoxO1
immunoreactivity in the control group (n = 6) and groups transduced with Ad-EGFP (n = 6), Ad-EGFP-CaV3.1 (n = 6), and Ad-EGFP-CaV3.1 in the presence of
NNC55-0396 (n = 6). **P < 0.01 vs. control and Ad-EGFP; +P < 0.05 vs. Ad-EGFP-CaV3.1 plus NNC55-0396. (C) Representative FoxO1 immunofluorescence (Left
column), DAPI fluorescence (Middle column), and their overlay images (Right column) in Ad-EGFP-transduced INS-1E cells (Upper row) and Ad-EGFP-CaV3.1-
transduced INS-1E cells in the absence (Middle row) and presence (Lower row) of NNC55-0396. Red and blue represent FoxO1 immunofluorescence and DAPI
fluorescence, respectively. (Scale bars, 10 μm.) (D) Quantification of FoxO1 immunofluorescence in the Ad-EGFP (n = 9), Ad-EGFP-CaV3.1 (n = 10), and Ad-
EGFP-CaV3.1 + NNC55-0396 (n = 8) groups. **P < 0.01 vs. Ad-EGFP and Ad-EGFP-CaV3.1 + NNC55-0396. FoxO1Fc, cytoplasmic FoxO1 immunofluorescence.
FoxO1Fn, nuclear FoxO1 immunofluorescence. (E) Sample FoxO1 immunofluorescence (Left column), DAPI fluorescence (Middle column), and their overlay
images (Right column) in Ad-EGFP-transduced INS-1E cells (Upper row) and Ad-EGFP-CaV3.1-transduced INS-1E cells without (Middle row) and with (Lower
row) exposure to tacrolimus. Red and blue represent FoxO1 immunofluorescence and DAPI fluorescence, respectively. (Scale bars, 10 μm.) (F) Quantitative
analysis of FoxO1 immunofluorescence in the Ad-EGFP (n = 9), Ad-EGFP-CaV3.1 (n = 12), and Ad-EGFP-CaV3.1 + tacrolimus (n = 9) groups. **P < 0.01 vs. Ad-
EGFP and Ad-EGFP-CaV3.1 + tacrolimus. FoxO1Fc, cytoplasmic FoxO1 immunofluorescence; FoxO1Fn, nuclear FoxO1 immunofluorescence. (G) Representative
blots of synaptotagmin III-, syntaxin 1A–, SNAP-25- and α-tubulin-immunoreactive bands in control islets and islets infected with Ad-EGFP or Ad-EGFP-CaV3.1.
(H) Quantifications of synaptotagmin III, syntaxin 1A, and SNAP-25 immunoreactivities in the control (n = 5 for SNAP-25, n = 7 for syntaxin 1A, and n = 7 for
synaptotagmin III), Ad-EGFP (n = 5 for SNAP-25, n = 7 for syntaxin 1A, and n = 7 for synaptotagmin III), and Ad-EGFP-CaV3.1 (n = 5 for SNAP-25, n = 7 for
syntaxin 1A, and n = 7 for synaptotagmin III) groups. **P < 0.01 vs. control and Ad-EGFP. (I) Representative syntaxin 1A (stx1A, first column), SNAP-25 (second
column), synaptotagmins III (sytIII, third column) and VII (sytVII, fourth column) immunofluorescence (red) overlaid with DAPI fluorescence (blue) in Ad-EGFP-
transduced (Upper row) and Ad-EGFP-CaV3.1-transduced INS-1E cells untreated (Middle row) and treated (Lower row) with NCC55-0396. (Scale bars, 10 μm.) (J)
Quantitative analysis of syntaxin 1A, SNAP-25, and synaptotagmin III and VII immunofluorescence in the Ad-EGFP (n = 14 for syntaxin 1A, n = 11 for SNAP-25,
n = 11 for synaptotagmin III, and n = 14 for synaptotagmin VII), Ad-EGFP-CaV3.1 (n = 10 for syntaxin 1A, n = 14 for SNAP-25, n = 10 for synaptotagmin III, and
n = 14 for synaptotagmin VII), and Ad-EGFP-CaV3.1 + NNC55-0396 (n = 13 for syntaxin 1A, n = 11 for SNAP-25, n = 11 for synaptotagmin III, and n = 16 for
synaptotagmin VII) groups. **P < 0.01 and *P < 0.05 vs. EGFP and Ad-EGFP-CaV3.1 + NNC55-0396. a.u., arbitrary units.




























Ad-EGFP-CaV3.1-infected islets to ameliorate hyperglycemia
in streptozotocin (STZ)-induced diabetic rats. These 3 groups of
islets were transplanted into the anterior chamber of the eye of
STZ-treated rats (Fig. 2A). All of them were well engrafted on the
iris and richly vascularized within 4 wk after transplantation, during
which both Ad-EGFP-CaV3.1- and Ad-EGFP-treated islets emitted
appreciable EGFP fluorescence (Fig. 2 B and C). STZ-treated rats
manifested overt hyperglycemia before islet transplantation (Fig.
2D). Importantly, a significant normalization of hyperglycemia oc-
curred in STZ-treated rats transplanted with either control islets or
islets infected with Ad-EGFP but not in STZ-treated rats trans-
planted with Ad-EGFP-CaV3.1-transduced islets (Fig. 2D). Indeed,
Ad-EGFP-CaV3.1-treated islets have no ability to ameliorate hy-
perglycemia in STZ-induced diabetic rats. Of note, no appreciable
differences were found in the islet backscatter signal, which reflects
functional islet cell mass (29), between control, Ad-EGFP-
transduced, and Ad-EGFP-CaV3.1-transduced islets (Fig. 2C).
This indicates that the enhanced expression of β cell CaV3.1
channels did not reach the extremely high level where these chan-
nels mediate exaggerated Ca2+ influx to cause Ca2+-dependent islet
cell damage, such as reduced insulin content, apoptosis, and
necrosis.
Transduction with Ad-EGFP-CaV3.1 Decreases Cytoplasmic p-FoxO1
and Induces FoxO1 Nuclear Retention through the CaV3.1 Channel–
Dependent Activation of Calcineurin. The unique ability of β cells
to accurately release insulin in response to glucose critically re-
lies on adequate expression of β cell–specific genes under the
control of a defined set of transcription factors, including FoxO1
(18, 30, 31). This transcription factor acts not only downstream of
complex Ca2+ signaling systems but also upstream of expression of
β cell exocytotic proteins (18, 31). This made us question if ele-
vated expression of CaV3.1 channels and resulting Ca
2+ influx
interfere with FoxO1 transcriptional action on β cell exocytotic
protein genes with consequent impaired glucose-stimulated insulin
secretion. We therefore quantified cytoplasmic phosphorylated
FoxO1 in insulin-secreting INS-1E cells subjected to different
treatments. It turned out that the relative abundance of cyto-
plasmic phosphorylated FoxO1 was significantly reduced in the
Ad-EGFP-CaV3.1 group in comparison to that in the control and
the Ad-EGFP groups as well as the group subjected to Ad-EGFP-
CaV3.1 infection followed by exposure to the highly selective CaV3
channel blocker NNC55-0396 (Fig. 3 A and B). All 4 groups
exhibited similar intensities of GAPDH immunoreactivity (Fig.
3A). The reduction of cytoplasmic phosphorylated FoxO1 induced
by elevated expression of CaV3.1 channels reflects decreased
phosphorylation and increased retention of FoxO1 in the nucleus
and suggests that the expression of β cell exocytotic protein genes
downstream of FoxO1 is reduced.
To detect up-expressed CaV3.1 channel–induced changes in
FoxO1 subcellular distribution and underlying mechanisms, we
immunocytochemically characterized cytoplasmic and nuclear
FoxO1 in INS-1E cells following Ad-EGFP-CaV3.1 transduction
and treatment with NNC55-0396 or the CaN inhibitor tacrolimus.
Fig. 3 C and E shows that FoxO1 immunofluorescence was more
intense in the nuclei but less intense in the cytoplasm of cells
transduced with Ad-EGFP-CaV3.1 than in those of Ad-EGFP-
transduced cells. As shown in Fig. 3 D and F, the ratio of nuclear
to cytoplasmic FoxO1 in the Ad-EGFP-CaV3.1 group significantly
increased compared to that in Ad-EGFP group. Importantly, the
effects were effectively ablated by treatment with NNC55-0396 or
tacrolimus (Fig. 3 C–F). These results demonstrate that Ad-EGFP-
CaV3.1 transduction indeed gives rise to FoxO1 nuclear retention
through the CaV3.1 channel–dependent activation of CaN. They
also suggest that the up-expressed CaV3.1-mediated Ca
2+ influx is
likely to constitutively hyperactivate CaN to make this phosphatase
powerful enough to reach and dephosphorylate nuclear p-FoxO1,
thereby preventing it from being extruded from the nucleus. In fact,
the constitutively hyperactivated CaN has been demonstrated to
dephosphorylate serine-256 of FoxO1 in ischemic neurons where
[Ca2+]i is pathologically high (17, 32).
Ad-EGFP-CaV3.1 Transduction Reduces Syntaxin 1A, SNAP-25, and
Synaptotagmin III in a CaV3.1 Channel–Dependent Manner. To ver-
ify if FoxO1 nuclear retention induced by up-expressed CaV3.1
channels reduces expression of β cell exocytotic protein genes,
we performed immunoquantification of syntaxin 1A, SNAP-25,
and synaptotagmins III and VII in rat islets and INS-1E cells.
Immunoblot analysis shows that Ad-EGFP-CaV3.1-treated islets
gave significantly weaker intensities of synaptotagmin III-, syntaxin
1A-, and SNAP-25-immunoreactive bands in comparison to con-
trol and Ad-EGFP-treated islets (Fig. 3 G and H). These 3 types
of islets exhibited similar intensities of α-tubulin-immunoreactive
bands (Fig. 3G). Quantitative immunocytochemistry reveals that
INS-1E cells transduced with Ad-EGFP-CaV3.1 exhibited signifi-
cant reduction in the immunofluorescence of syntaxin 1A, SNAP-
25, and synaptotagmin III compared to Ad-EGFP-infected cells
(Fig. 3 I and J). Interestingly, the reduction was efficiently reversed
following NNC55-0396 treatment (Fig. 3 I and J). However, the
critical Ca2+ sensor synaptotagmin VII that triggers insulin exo-
cytosis only underwent marginal changes following the same
treatments (Fig. 3 I and J). These results verify that FoxO1 nuclear
retention resulting from Ad-EGFP-CaV3.1 transduction suppresses
transcription of syntaxin 1A, SNAP-25, and synaptotagmin III,
which are critical for glucose-stimulated insulin secretion (6,
33–35). This is consistent with the fact that FoxO1 can bind
to the promotor regions of SNARE genes and suppress their
expression (19).
As a matter of fact, complex interactions between multiple
genetic variants and numerous environmental factors result in a
number of etiologically heterogeneous subgroups of diabetes
(36). Some of them are characterized by derangements in a plethora
of molecular and cellular events, including CaV channel–centered
Fig. 4. Model depicting how elevated expression of β cell CaV3.1 channels
impairs insulin release and glucose homeostasis. Unphosphorylated FoxO1 can
bind to the promotor region of certain exocytotic protein genes to suppress
their transcription. Under physiological conditions, however, the transcrip-
tional suppression of FoxO1 hardly occurs since FoxO1 is phosphorylated and
extruded from the nucleus to the cytoplasm. This ensures precise tran-
scriptomics, correct differentiation, and adequate insulin secretion capacity of
the β cell, thereby maintaining satisfactory glucose homeostasis in the body.
Pathologically up-expressed CaV3.1 channels mediate abnormal Ca
2+ influx
that constitutively hyperactivates CaN. Constitutively hyperactivated CaN de-
phosphorylates FoxO1 in nuclei, resulting in its nuclear accumulation. This
leads to transcriptional suppression of the exocytotic proteins syntaxin 1A,
SNAP-25, and synaptotagmin III, resulting in impaired insulin secretion and
aberrant glucose homeostasis. IG, insulin granule.





















molecular networks in β cells (6, 37, 38). De novo up-expression of
β cell CaV3.1 channels plus pharmacological inhibition and char-
acterization of the eventual ability of these genetically transduced
islets to secrete insulin and normalize hyperglycemia enable us
to dissect the role of elevated expression of β cell CaV3.1
channels in the development of diabetes from the aforemen-
tioned complexity. Furthermore, the combination of such ap-
proaches with analysis of the FoxO1 signaling pathway allowed
us to identify a pathway from the up-expressed β cell CaV3.1
channels to transcriptional loci suppressing the expression of
some exocytotic protein genes in the β cell. Limitations of the
present work are due to the difficulty in obtaining islets from a
large population of human donors with diabetes for experiments
and recruiting sufficient numbers of patients with gain-of-function
mutation of the CaV3.1 gene or epigenetic up-regulation of CaV3.1
gene expression for clinical trials. In this context, etiological het-
erogeneity in diabetes may hinder these basic and clinical studies
since small sample sizes can bring about potential bias of experi-
mental results (36). Our work suggests that enhanced expression of
β cell CaV3.1 channels plays a causal role in pathogenesis of hu-
man diabetes. This remains to be verified by detailed clinical
studies.
Conclusions
We demonstrated the feasibility of using Ad-EGFP-CaV3.1 to
elevate CaV3.1 channel expression in islets. The elevated expression
of CaV3.1 channels not only impairs both basal insulin release and
first-phase glucose-stimulated insulin secretion with no influence
on second-phase insulin response but also disables islets from
normalizing hyperglycemia in STZ-induced diabetic rats. This
happens since up-expressed CaV3.1 channels mediate excessive Ca
2+
influx, resulting in pathological elevation of basal [Ca2+]i, which
sequentially brings about activation of CaN, dephosphorylation,
and nuclear retention of FoxO1 and FoxO1-mediated suppression
of syntaxin 1A, SNAP-25, and synaptotagmin III gene transcrip-
tion in the β cell (Fig. 4). Enhanced T-type Ca2+ currents through
β cell CaV3.1 channels thus play a significant role in the devel-
opment of a diabetic phenotype and suggest that β cell–specific
blockade of these channels may be considered as an approach to
treat diabetes.
Methods
Animals. Specific pathogen-free Wistar rats at 8 to 12 wk of age were obtained
from Charles River Laboratories (Sulzfeld, Germany) and maintained on a
regular light–dark cycle (lights on at 0700 and off at 1900) in temperature- and
humidity-controlled rooms and had free access to food pellets and tap water.
All animal experiments were conducted according to the guidelines of the
Animal Care Committee of Karolinska Institutet.
Additional experimental procedures are presented in the SI Appendix.
Data Availability. All of the data, associated protocols, and materials for this
study are available within the paper and its SI Appendix.
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